Combined SGLT2 and GLP-1 Therapy for Type 2 Diabetes: Cardiovascular and Renal Benefits
Recent clinical meta-analyses indicate that combining Glucagon-Like Peptide-1 (GLP-1) receptor agonists with Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors significantly reduces major adverse cardiovascular events (MACE) and slows the progression of chronic ... Read More